Kura Oncology (NASDAQ:KURA) Shares Gap Up Following Strong Earnings
by Scott Moore · The Cerbat GemShares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $9.94, but opened at $10.61. Kura Oncology shares last traded at $11.1790, with a volume of 1,178,828 shares traded.
The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million.
Key Headlines Impacting Kura Oncology
Here are the key news stories impacting Kura Oncology this week:
- Positive Sentiment: KOMZIFTI momentum strengthened. The acute myeloid leukemia treatment generated $9.1 million in net product revenue, a 57% increase from the first quarter, while new patient starts rose 35% to approximately 115. This commercial growth suggests increasing adoption of Kura’s marketed product. Kura Oncology Reports Second Quarter 2026 Financial Results
- Positive Sentiment: Financial results exceeded expectations. Kura reported a second-quarter loss of $0.77 per share, narrower than the $0.88–$0.89 analyst consensus, while revenue of $20.87 million topped expectations of approximately $20.16 million. The earnings beat may be contributing to the stock’s strength. Kura Oncology Reports Q2 Loss and Beats Revenue Estimates
- Positive Sentiment: Collaboration revenue is expected to provide additional support. Management outlined approximately $90 million to $110 million of collaboration revenue for 2027, improving the company’s medium-term financial visibility. Kura Outlines 2027 Collaboration Revenue
- Neutral Sentiment: Clinical catalysts remain longer term. Kura is targeting topline results from the KOMET-017 study in 2028, leaving investors dependent on commercial execution and collaboration revenue in the nearer term. Kura Oncology Q2 2026 Earnings Call Transcript
- Negative Sentiment: Kura remains deeply unprofitable. Despite beating estimates, the company posted a substantial quarterly loss, with a reported negative net margin of 411.19%. Continued operating losses could limit valuation upside until product and collaboration revenue scale further. Kura Oncology Q2 2026 Earnings Call Summary
Analyst Ratings Changes
Several research firms have recently weighed in on KURA. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a report on Monday, June 15th. Oppenheimer set a $24.00 price objective on Kura Oncology in a research note on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Friday, July 17th. Wedbush upped their target price on Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.62.
View Our Latest Stock Analysis on Kura Oncology
Insider Buying and Selling
In other news, insider Mollie Leoni sold 84,929 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the transaction, the insider owned 182,345 shares of the company’s stock, valued at $1,790,627.90. This represents a 31.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.60% of the stock is currently owned by corporate insiders.
Institutional Trading of Kura Oncology
A number of hedge funds have recently made changes to their positions in KURA. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Kura Oncology by 69.7% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock worth $6,240,000 after purchasing an additional 233,633 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Kura Oncology by 32.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after buying an additional 348,127 shares in the last quarter. UBS Group AG raised its holdings in shares of Kura Oncology by 118.3% during the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock valued at $11,014,000 after buying an additional 574,455 shares in the last quarter. Nan Fung Trinity HK Ltd. lifted its position in Kura Oncology by 317.9% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock worth $10,025,000 after buying an additional 734,000 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in Kura Oncology by 285.6% in the first quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock worth $1,291,000 after buying an additional 117,650 shares in the last quarter.
Kura Oncology Stock Performance
The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The company has a 50 day simple moving average of $10.15 and a 200-day simple moving average of $9.31. The firm has a market cap of $980.55 million, a PE ratio of -3.30 and a beta of 0.38.
About Kura Oncology
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.